[HTML][HTML] Methods and biomarkers for early detection, prediction, and diagnosis of colorectal cancer
Y Zhang, Y Wang, B Zhang, P Li, Y Zhao - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Colorectal cancer (CRC) is one of the most common digestive diseases worldwide. It has
steadily ascended to the top three cancers in terms of incidence and mortality. The primary …
steadily ascended to the top three cancers in terms of incidence and mortality. The primary …
Genomic and transcriptomic determinants of therapy resistance and immune landscape evolution during anti-EGFR treatment in colorectal cancer
Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a
subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the …
Prognostic role and clinicopathological features of SMAD4 gene mutation in colorectal cancer: a systematic review and meta-analysis
T Fang, T Liang, Y Wang, H Wu, S Liu, L **e… - BMC …, 2021 - Springer
Abstract Background Approximately 5.0–24.2% of colorectal cancers (CRCs) have
inactivating mutations in SMAD4, making it one of the frequently mutated genes in CRC. We …
inactivating mutations in SMAD4, making it one of the frequently mutated genes in CRC. We …
SMAD4 mutations do not preclude epithelial–mesenchymal transition in colorectal cancer
P Frey, A Devisme, K Rose, M Schrempp, V Freihen… - Oncogene, 2022 - nature.com
Transforming growth factor beta (TGFβ) superfamily signaling is a prime inducer of epithelial-
mesenchymal transitions (EMT) that foster cancer cell invasion and metastasis, a major …
mesenchymal transitions (EMT) that foster cancer cell invasion and metastasis, a major …
Carbon-based nanomaterials as drug delivery agents for colorectal cancer: clinical preface to colorectal cancer citing their markers and existing theranostic …
J Ma, G Wang, X Ding, F Wang, C Zhu, Y Rong - ACS omega, 2023 - ACS Publications
Colorectal cancer (CRC) is one of the universally established cancers with a higher
incidence rate. Novel progression toward cancer prevention and cancer care among …
incidence rate. Novel progression toward cancer prevention and cancer care among …
[HTML][HTML] Molecular methods for colorectal cancer screening: Progress with next-generation sequencing evolution
Currently, colorectal cancer (CRC) represents the third most common malignancy and the
second most deadly cancer worldwide, with a higher incidence in developed countries. Like …
second most deadly cancer worldwide, with a higher incidence in developed countries. Like …
Cetuximab in locally advanced head and neck squamous cell carcinoma: Biological mechanisms involved in efficacy, toxicity and resistance
E Muraro, G Fanetti, V Lupato, V Giacomarra… - Critical Reviews in …, 2021 - Elsevier
Since its introduction, the use of cetuximab in the treatment of head and neck squamous cell
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …
carcinoma (HNSCC) has experienced an evolution. Currently, cetuximab associated with …
Targeting EGFR and RAS/RAF signaling in the treatment of metastatic colorectal cancer: from current treatment strategies to future perspectives
T Mizukami, N Izawa, TE Nakajima, Y Sunakawa - Drugs, 2019 - Springer
The epidermal growth factor receptor (EGFR) and RAS/RAF signaling pathway plays pivotal
roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two …
roles in tumor progression via proliferation, survival, invasion, and immune evasion. Two …
Circulating tumor DNA is capable of monitoring the therapeutic response and resistance in advanced colorectal cancer patients undergoing combined target and …
H Cao, X Liu, Y Chen, P Yang, T Huang, L Song… - Frontiers in …, 2020 - frontiersin.org
Colorectal cancer (CRC) is a highly lethal disease worldwide. The majority of patients
receiving targeted therapy or chemotherapy develop drug resistance, while its molecular …
receiving targeted therapy or chemotherapy develop drug resistance, while its molecular …
[HTML][HTML] Specific genomic alterations and prognostic analysis of perihilar cholangiocarcinoma and distal cholangiocarcinoma
Y Zheng, Y Qin, W Gong, H Li, B Li… - Journal of …, 2021 - ncbi.nlm.nih.gov
Background Cholangiocarcinoma (CCA), which consists of intrahepatic CCA (iCCA),
perihilar CCA (pCCA), and distal CCA (dCCA), is an aggressive malignancy worldwide …
perihilar CCA (pCCA), and distal CCA (dCCA), is an aggressive malignancy worldwide …